Salix Total Value Analsys
Salix Pharmaceuticals Ltd is at this time projected to have valuation of 5.37 B with market capitalization of 5.33 B, debt of 872.69 M, and cash on hands of 817.72 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Salix fundamentals
before making equity appraisal based on the enterprise value of the company
Salix Investor Information
About 99.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.12. Salix Pharmaceuticals Ltd had not issued any dividends in recent years. This company had 3:2 split on July 13, 2004. Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices used in the treatment of various gastrointestinal diseases in the United States. To find out more about SALIX PHARM DEL contact Carolyn Logan at 919-862-1000 or learn more at http://www.salix.com.
Salix Asset Utilization
Salix Pharmaceuticals exercises its assets roughly 7.42 %, realizing $0.07 for each dollar of assets held by the company. A flourishing assets utilization indicates the company is being more effective with each dollar of assets it has. In other words assets utilization of Salix shows how effective it operates for each dollar spent on its assets
Salix Ownership Allocation (%)
Salix Pharmaceuticals shows a total of sixty-two million nine hundred thousand outstanding shares
. Majority of Salix Pharmaceuticals outstanding shares
are owned by other institutions
. These institutional investers are referred to non-private investors that are looking to take positions in Salix to benefit from reduced commissions. Consequently, institutions are subject to different set of regulations than regular investors in Salix Pharmaceuticals. Please pay attention to any change in the institutional holdings of Salix Pharmaceuticals Ltd as this could imply that something significant has changed or about to change at the company. Also note that roughly six hundred twenty-nine thousand invesors are currently shorting Salix expressing very little confidence in its future performance.
Salix Profitability Analysis
The company reported previous year revenue of 874.4 M. Net Income was 108.39 M with profit before overhead, payroll, taxes, and interest of 610.85 M.
Salix Debt Analysis
SALIX PHARM DEL currently holds about 817.72 M in cash with 66.25 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.0.
The company currently holds 872.69 M in liabilities with Debt to Equity (D/E) ratio of 1.29 which is about average as compared to similar companies. Salix Pharmaceuticals Ltd has Current Ratio of 4.21 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.